Policy
FDA Slaps New Safety Warning on GLP-1 Drugs
The Brief
- The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information.
- The update adds a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), described as rare but potentially blinding.
Why it matters
Prescribers and patients using GLP-1 drugs will see a new labeled warning about a rare but serious eye risk, which may affect how the drugs are discussed and monitored.
Who’s affected
- patients taking GLP-1 drugs
- prescribing physicians
- ophthalmologists
- #glp-1
- #drug safety
- #naion
- #fda
- #ophthalmology
(MedPage Today) -- The FDA is requiring manufacturers of all GLP-1 drugs to update their prescribing information to include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but potentially blinding...